Drugs / rM28
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00204594 | Oct 2005 → Dec 2007 | melanoma | University Hospital Tuebingen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rM28 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00204594 ↗ |
| Route | Other | “intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs” NCT00204594 ↗ |
| Target | CD28 | “The antibody is directed against epitops of human CD28” NCT00204594 ↗ |